Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
The addition of capivasertib (Truqap) to fulvestrant (Faslodex) led to an improvement in time to second progression (PFS2) compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast …